Evolving concepts of stroke and stroke management in South Africa: Quo vadis? by Taylor, A & Ntusi, N A B
69       February 2019, Vol. 109, No. 2
CME
Definition of stroke
Stroke is traditionally defined as a neurological deficit attributed to 
an acute focal injury of the central nervous system (CNS), which 
occurs on a vascular basis. Stroke subtypes include ischaemic 
stroke/cerebral infarction, intracerebral haemorrhage (ICH) and 
subarachnoid haemorrhage (SAH). Stroke is a major cause of 
disability and death worldwide. Despite its global impact, the term 
stroke is not consistently defined in clinical practice, in clinical 
research or in assessment of the public’s health. Advances in basic 
science, neuropathology, and neuroimaging have improved the 
understanding of ischaemia, infarction, and haemorrhage in the 
CNS.[1] Updated definitions of stroke and stroke subtypes are 
provided in Box 1.
Stroke classification and aetiology
Stroke is classified into two major types: brain ischaemia and 
brain haemorrhage (due to ICH and SAH). Ischaemia followed by 
recirculation into an infarcted area may convert into haemorrhagic 
infarcts and may aggravate cerebral oedema owing to disruption of the 
blood-brain barrier. Acute ischaemic strokes (AIS) may be secondary 
to atherosclerosis, thrombosis (i.e. local in situ obstruction of an 
artery from arteriosclerosis, dissection or fibromuscular dysplasia), 
embolism (i.e. particles of debris originating elsewhere that block 
arterial access to a particular brain region) or systemic hypoperfusion. 
Blood disorders causing coagulopathy are an uncommon primary 
cause of stroke.
Transient ischaemic attack (TIA) is traditionally defined clinically 
by the temporary nature of the associated neurological symptoms, 
which last <24 hours owing to neurological dysfunction caused 
by focal brain, spinal cord or retinal ischaemia, without acute 
infarction. The definition is changing with recognition that transient 
neurological symptoms are frequently associated with permanent 
brain tissue injury and the differentiation between TIA and AIS is 
arbitrary, as the two entities share the same spectrum. 
The causes of AIS include:
• Large-vessel disease – atherosclerosis, dissection, Takayasu 
arteritis, giant-cell arteritis and fibromuscular dysplasia.
• Small-vessel disease – lipohyalinosis, fibrinoid degeneration and 
microatheroma formation.
• Cardioembolic disease – atrial fibrillation and paroxysmal atrial 
fibrillation, rheumatic mitral or aortic valve disease, bioprosthetic 
and mechanical heart valves, atrial or ventricular thrombus, sick 
sinus syndrome, sustained atrial flutter, recent myocardial infarction 
(within 1 month), chronic myocardial infarction together with 
ejection fraction <28%, symptomatic congestive heart failure with 
ejection fraction <30%, dilated cardiomyopathy, Libman-Sacks 
endocarditis, infective endocarditis, papillary fibro-elastoma, left 
atrial myxoma and coronary artery bypass graft surgery.
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Box 1. Definition of stroke
The term stroke should be broadly used to include all of the following definitions:
CNS infarction. Brain, spinal cord or retinal cell death attributable to ischaemia, based on: (i) pathological, imaging or other objective evidence 
of cerebral, spinal cord or retinal focal ischaemic injury in a defined vascular distribution; or (ii) clinical evidence of cerebral, spinal cord 
or retinal focal ischaemic injury based on symptoms persisting ≥24 hours or until death, excluding other aetiologies. (Note: CNS infarction 
includes haemorrhagic infarctions, types I and II.)
Ischaemic stroke. An episode of neurological dysfunction caused by focal cerebral, spinal or retinal infarction. (Note: evidence of CNS 
infarction is defined above.)
Silent CNS infarction. Imaging or neuropathological evidence of CNS infarction, without a history of acute neurological dysfunction 
attributable to the lesion.
Intracerebral haemorrhage. A focal collection of blood within the brain parenchyma or ventricular system that is not caused by trauma. (Note: 
intracerebral haemorrhage includes parenchymal haemorrhages after CNS infarction, types I and II.)
Stroke caused by intracerebral haemorrhage. Rapidly developing clinical signs of neurological dysfunction attributable to a focal collection of 
blood within the brain parenchyma or ventricular system that is not caused by trauma.
Silent cerebral haemorrhage. A focal collection of chronic blood products within the brain parenchyma, subarachnoid space or ventricular 
system on neuroimaging or neuropathological examination that is not caused by trauma and without a history of acute neurological dysfunction 
attributable to the lesion.
Subarachnoid haemorrhage. Bleeding into the subarachnoid space (the space between the arachnoid membrane and the pia mater of the brain 
or spinal cord).
Stroke caused by subarachnoid haemorrhage. Rapidly developing signs of neurological dysfunction and/or headache because of bleeding into 
the subarachnoid space (the space between the arachnoid membrane and the pia mater of the brain or spinal cord), which is not caused by 
trauma.
Stroke caused by cerebral venous thrombosis. Infarction or haemorrhage in the brain, spinal cord or retina because of thrombosis of a cerebral 
venous structure. Symptoms or signs caused by reversible oedema without infarction or haemorrhage do not qualify as stroke.
Stroke, not otherwise specified. An episode of acute neurological dysfunction presumed to be caused by ischaemia or haemorrhage, persisting 
≥24 hours or until death, but without sufficient evidence to be classified as one of the above.
CNS = central nervous system.
Adapted from Sacco et al.[1] 
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• Systemic hypoperfusion – cardiac pump failure caused by cardiac 
arrest, arrhythmia, acute myocardial ischaemia, pulmonary embo-
lism, pericardial effusion or bleeding. Hypoxaemia may further 
reduce the amount of oxygen carried to the brain.
• Venous sinus thrombosis.
• Blood disorders – sickle cell anaemia, polycythaemia vera, essential 
thrombocytosis, heparin-induced thrombocytopenia, protein C or 
S deficiency (acquired or congenital), prothrombin gene mutation, 
factor V Leiden (resistance to activated protein C), antithrom-
bin III deficiency, antiphospholipid syndrome and hyper homo-
cysteinaemia.
Stroke epidemiology
Globally, the proportion of strokes due to ischaemia is 68%, while 
haemorrhagic stroke (ICH and SAH combined) accounts for 32%. 
There is a higher incidence of haemorrhagic stroke in low- and 
middle-income countries (LMICs).[2] In the USA, as in many high-
income settings, the proportion of all strokes due to ischaemia 
approaches 90%.[3] Worldwide, stroke is the second most common 
cause of mortality and the third most common cause of disability.[4] In 
China, which has the greatest burden of stroke in the world, the age-
standardised prevalence, incidence and mortality rates are estimated 
to be 1 115, 247 and 115 per 100 000 person-years, respectively.[5] 
The overall rate of stroke-related mortality is decreasing in high- and 
low-income countries, but the absolute number of people with stroke, 
stroke survivors, stroke-related deaths, and the global burden of 
stroke-related disability are high and increasing.[6] Men have a higher 
incidence of stroke than women at younger but not older ages, with 
the incidence reversed and higher for women by ≥75 years of age.[3] 
In the USA, blacks have an increased risk of stroke compared with 
whites.[7]
In 2010, stroke was responsible for 5.3 million deaths or 10% 
of deaths worldwide.[8] The absolute number of people affected by 
stroke has been increasing yearly since 1990, along with the numbers 
of disabled stroke survivors and stroke-related deaths.[2] If current 
trends continue, by 2030 there will be 20 million annual deaths caused 
by stroke and 70 million stroke survivors worldwide. More than 80% 
of the stroke burden occurs in LMICs; yet, reliable data on stroke 
epidemiology, especially incidence and morbidity, are scarce in these 
settings, particularly in many African countries.[9] Epidemiological 
data are required to better describe trends and to develop appropriate 
cost-effective prevention and treatment strategies. In the absence 
of up-to-date estimates of the epidemiological burden of stroke, 
the economic impact of stroke is possibly underestimated. Global 
estimates, mostly derived from high-income countries, show that 3% 
of total health system resources are devoted to stroke.[10] 
Stroke in South Africa
Much of the population of South Africa (SA) is undergoing a 
rapid epidemiological transition with increased exposure to, and 
development of, stroke risk factors, together with ageing. In SA, stroke 
is responsible for ~25 000 deaths annually and 95 000 years lived with 
disability.[11] In 2000, stroke was the third most common cause of 
death in SA, after HIV/AIDS and coronary artery disease.[12] Black 
women had the highest mortality rate from stroke (160 per 100 000), 
while mortality was lowest in white men (72 per 100 000). Deaths 
in the black population were double those in the white population. 
The risk of stroke increases with age: there are more stroke deaths 
in older South Africans, where stroke is the most common cause of 
death of people >50 years.[13] The Southern African Stroke Prevention 
Initiative (SASpi) study provided the only community-based data on 
the prevalence of stroke in SA. The age-standardised prevalence of 
stroke was 290 per 100 000, and the crude prevalence in rural South 
Africans was 300 per 100 000.[14] Stroke prevalence in urban areas is 
probably higher. The SASpi study showed that there were far more 
disabled stroke survivors in rural SA than in Tanzania, and a similar 
number in New Zealand, which has a high-income population with 
(most likely) a higher incidence of stroke than SA.[14] More recently, a 
crude stroke rate of 244 per 100 000 person-years was reported in the 
Agincourt subdistrict, Mpumalanga Province, and 1 070 disability-
adjusted life years (DALYs) were lost owing to stroke, indicating very 
high rates of stroke incidence and disability in rural SA.[8] 
The SA National Burden of Disease Study estimated DALYs and 
years of life lost owing to premature death and found that, despite 
the high prevalence of HIV/AIDS, violence and trauma, stroke is 
the 8th most important cause of years of life lost owing to illness, 
and the 9th most important cause of disability in SA.[12] The SA 
Comparative Risk Assessment Collaborating Group estimated the 
contribution of 8 risk factors to stroke: hypertension (52%), tobacco 
use (24%), excess body weight (18%), high cholesterol (15%), physical 
inactivity (12%), low fruit and vegetable intake (12%), diabetes (8%) 
and alcohol consumption (8%).[15] Stroke management, especially in 
young South Africans, is often complicated by the high prevalence of 
HIV/AIDS.[16]
In 2010, the SA Stroke Society (SASS) published guidelines on 
the management of stroke and TIA with the objective of placing 
recommendations in the current SA context, and grading existing 
evidence according to the level of scientific rigour.[17]
Stroke management
Most SA patients with stroke seen in primary healthcare settings 
struggle to regularly access basic medicine, such as aspirin, statins, 
and antihypertensive and antidiabetic medications. Furthermore, 
because of the limited number of stroke units, which are situated 
almost exclusively in large urban centres, there are significant 
disparities in the quality of care that stroke patients receive in SA. 
Access to reperfusion therapies is not universally accessible, even in 
SA urban centres.
Despite the high disease burden, some progress has been made 
and stroke is no longer a hopeless condition. Dedicated stroke units 
were the first step in improving care, with several randomised trials 
showing that death and handicap could be prevented in 50 patients 
for every 1 000 admitted.[2,17] Intravenous thrombolysis offered the next 
step forward, with death and disability prevented in 143 patients for 
every 1 000 treated with intravenous recombinant tissue plasminogen 
activator therapy within 3 hours of symptom onset.[18] It was later 
shown that the 3-hour time window for thrombolysis administration 
could be increased to 4.5 hours; and, if the trial entry and exclusion 
criteria were met, up to 30% of all AIS patients could benefit. 
The most recent evolution has been mechanical thrombectomy, 
performed in the catheterisation laboratory, where the occluding 
cerebral vessel clot is extracted. Thrombectomy is a highly effective 
treatment, preventing death and disability in 200 patients for every 
1 000 treated. Treatment should not only be directed at cure; however, 
those who survive with disability should be offered rehabilitation – 
helping them to recover and achieve their maximum potential, as well 
as reintegrate into society.
For patients to benefit from these advances, we need to get 
them to the correct facilities in time for treatment. This requires 
co-ordination of services, including emergency assessment, transfer 
and delivery to stroke centres. This is most effective in countries 
such as Switzerland, where stroke referral is legislated. Being fully 
informed regarding what is possible, is the first step in improving 
care, which is the purpose of this issue of CME. 
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In this CME, 3 articles cover different aspects of stroke management. 
All of these services are currently available in SA and we need to 
ensure that all patients can access them. In the first article, Bateman[20] 
comprehensively reviews the management of AIS. In the next article, 
Harrichandparsad[21] gives an update on the history, current evidence, 
patient selection and practical aspects of mechanical thrombectomy 
for AIS, and in the last article, Whitehead and Baalbergen[22] 
remind us of the principles of post-stroke rehabilitation. Post-stroke 
rehabilitation is delivered by an interdisciplinary team experienced in 
the rehabilitation process, with the aim of improving patient outcomes 
by decreasing the chance of developing secondary complications 
and maximising a patient’s independence 
despite their impairments.
It is our hope that this update on stroke 
management will improve the management 
of stroke in SA.
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